Google
Trusted Resources: News & Events
Latest announcements and gatherings
Emmaus Medical, Inc. Selects AmerisourceBergen to Support the Launch of EndariTM (L-glutamine oral powder)
AmerisourceBergen, a global healthcare solutions leader, today announced that US Bioservices, an independent specialty pharmacy, has been selected by Emmaus Medical, Inc. as the specialty pharmacy for EndariTM (L-glutamine oral powder), for the treatment of patients with sickle cell disease.
The U.S. Food and Drug Administration approved Endari on July 7, 2017 for adult and pediatric patients 5 years of age and older to reduce acute complications of sickle cell disease. Endari is the first approved treatment for sickle cell disease in pediatric patients and the first new treatment available in nearly 20 years for adults.
As part of this partnership, Emmaus will leverage the breadth of AmerisourceBergen’s integrated commercialization solutions to support adherence and realize the best possible outcomes for patients. In addition to utilizing the comprehensive clinical services of US Bioservices, Emmaus will also collaborate with AmerisourceBergen’s ASD Healthcare and ICS.
+myBinderRelated Content
-
A new Sickle Cell Disease Drug Holds Much Promise but Most Sufferers Won’t be Able to Afford itThe regulatory approval of a groundbreak...
-
The Opioid Drug Epidemic and Sickle Cell Disease: Guilt by AssociationIn 2008, for the first time in Centers f...
-
Pain and opioid use after reversal of sickle cell disease following hematopoietic stem cell transplantPain is the most common symptom of sickl...
-
Sisterly bond behind sickle-cell curehttps://www.youtube.com/watch?v=9S-xVGsR...
-
Siklos®, the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now availab...Medunik USA, a company dedicated to impr...
-
Prolong Pharma’s Sanguinate Shows Promise in Reverting Shape of Red Blood Cells in SCDProlong Pharmaceuticals’ investigation...
-
MARAC Advisory Statement: Gene Therapy & Bone Marrow TherapiesPlease note: A previous version of this ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.